[Therapy of bronchopulmonary infection in smokers].

The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23). The drug was used orally in a dose of 1 g once a day. The patients were divided into 2 groups: group 1 included patients with aggravation of chronic bronchitis and group 2 included patients with bacterial pneumonia.

[Current possibilities and perspectives of the combined treatment of patients with severe bronchopulmonary diseases].

Complex treatment with ceftriaxone (or ceftazidime) and intravenous immunoglobulin G (Biaven V. I.) was performed at 21 patients with severe pneumonia and tracheobronchitis complicated by immunedeficient status (myasthenia, diabetes mellitus etc).

[Clinico-laboratory assessment of oframax (cefriaxone) in the treatment of infectious-inflammatory diseases].

Aim: To try efficacy and safety of ophramax (cephtriaxon) made in India ("Ranbaxy") in infectious-inflammatory diseases treated in a general hospital.

Material And Methods: Ophramax was given in a dose 1 to 4 g/day to 23 patients with pneumonia, chronic bronchitis, soft tissue infection, enterocolitis, etc. Therapeutic effect was examined with bacteriological identification of the infective agents, antibioticograms, agar diffusion test.